NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...
Boehringer Ingelheim announced a license and collaboration agreement with Simcere Pharmaceuticals to develop Simcere’s ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
From Dupixent to Tezspire and verekitug, explore emerging sinusitis treatments and the race to improve chronic rhinosinusitis ...
Black Americans die younger than their White counterparts, with an estimated 1.63 million "excess" deaths having occurred ...
Primary biliary cholangitis (PBC) is a rare chronic autoimmune cholangiopathy that mainly affects middle-aged women, ...
Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer ...
Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...
Heart attacks are often thought of as a plumbing issue, the result of a blockage preventing blood from flowing through one of ...
A new study published in Otolaryngology–Head and Neck Surgery reveals that glucagon-like peptide-1 receptor agonists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results